NO20060022L - Stabile sammensetninger av atorvastatin fremstilt ved vat granulering - Google Patents

Stabile sammensetninger av atorvastatin fremstilt ved vat granulering

Info

Publication number
NO20060022L
NO20060022L NO20060022A NO20060022A NO20060022L NO 20060022 L NO20060022 L NO 20060022L NO 20060022 A NO20060022 A NO 20060022A NO 20060022 A NO20060022 A NO 20060022A NO 20060022 L NO20060022 L NO 20060022L
Authority
NO
Norway
Prior art keywords
atorvastatin
granulation
cotton
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
NO20060022A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Bruce Fergione
Barbara Alice Johnson
Kenneth Craig Waterman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20060022L publication Critical patent/NO20060022L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
NO20060022A 2003-06-12 2006-01-03 Stabile sammensetninger av atorvastatin fremstilt ved vat granulering NO20060022L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12
PCT/IB2004/001862 WO2004110431A1 (fr) 2003-06-12 2004-06-01 Compositions stables d'atorvastatine preparees par granulation par voie humide

Publications (1)

Publication Number Publication Date
NO20060022L true NO20060022L (no) 2006-01-03

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060022A NO20060022L (no) 2003-06-12 2006-01-03 Stabile sammensetninger av atorvastatin fremstilt ved vat granulering

Country Status (15)

Country Link
EP (1) EP1635814A1 (fr)
JP (1) JP2006527260A (fr)
KR (1) KR100814218B1 (fr)
CN (1) CN100434069C (fr)
AR (1) AR044774A1 (fr)
AU (1) AU2004246868B2 (fr)
BR (1) BRPI0411344A (fr)
CA (1) CA2465565A1 (fr)
CO (1) CO5650230A2 (fr)
MX (1) MXPA05013281A (fr)
NO (1) NO20060022L (fr)
NZ (1) NZ543337A (fr)
RU (1) RU2332211C2 (fr)
TW (1) TW200503690A (fr)
WO (1) WO2004110431A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2009000286A1 (fr) * 2007-06-25 2008-12-31 Parmatheen S.A. Formulation pharmaceutique améliorée contenant un inhibiteur de la hmg-coa réductase et son procédé de préparation
KR20100125346A (ko) * 2008-02-27 2010-11-30 토멘 메디칼 아게 임플란트 및 이의 제조 방법
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
RU2404767C1 (ru) * 2009-08-11 2010-11-27 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
LT3470063T (lt) * 2012-11-02 2025-02-10 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
CA2954840A1 (fr) * 2014-07-25 2016-01-28 Novartis Ag Formulation de comprime de 2-fluoro-n-methyl-4-[7-(quinoline -6-ylmethyl) imidazo[1,2-b] [1,2,4]triazine -2-yl]benzamide
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
WO2016145132A1 (fr) * 2015-03-12 2016-09-15 Fmc Corporation Dispersions solides
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
CA2406574C (fr) * 2000-04-10 2006-12-05 Teva Pharmaceutical Industries, Ltd. Compositions pharmaceutiques stables contenant des acides 7-substitues-3,5-dihydroxyheptanoiques ou acides 7-substitues-3,5-dihydroxyheptenoiques
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (fr) * 2001-01-26 2002-07-31 Pfizer Products Inc. Formulation pharmaceutique présentant des propriétés de cohesion et de compressibilité améliorées
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1291017A3 (fr) * 2001-09-10 2003-07-02 Warner-Lambert Company Utilisation de statines pour prévenir la formation d'osteoclastes

Also Published As

Publication number Publication date
CN100434069C (zh) 2008-11-19
CO5650230A2 (es) 2006-06-30
BRPI0411344A (pt) 2006-07-11
AR044774A1 (es) 2005-10-05
RU2332211C2 (ru) 2008-08-27
NZ543337A (en) 2008-03-28
TW200503690A (en) 2005-02-01
KR100814218B1 (ko) 2008-03-17
CA2465565A1 (fr) 2004-12-12
CN1805741A (zh) 2006-07-19
WO2004110431A1 (fr) 2004-12-23
AU2004246868B2 (en) 2008-01-17
MXPA05013281A (es) 2006-03-09
RU2005136745A (ru) 2006-07-27
JP2006527260A (ja) 2006-11-30
KR20060020666A (ko) 2006-03-06
AU2004246868A1 (en) 2004-12-23
EP1635814A1 (fr) 2006-03-22

Similar Documents

Publication Publication Date Title
NO20060022L (no) Stabile sammensetninger av atorvastatin fremstilt ved vat granulering
TW200509905A (en) Pharmaceutical compositions of atorvastatin
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
WO2005034908A3 (fr) Forme posologique solide comprenant une fibrate et une statine
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
MXPA05012955A (es) Composiciones farmaceuticas de atorvastatina.
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
NO20061640L (no) Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
NO20064670L (no) Galeniske formuleringer av organiske forbindelser
LU92166I2 (fr) Glycopyrronium ou un de ses sels
MA27809A1 (fr) Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
WO2006118948A3 (fr) Compositions therapeutiques
MY138023A (en) Compositions and process for preparing cleansing bars comprising low levels of soluble surfactant for enhanced fragrance deposition/longevity
EA200100871A1 (ru) Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения
ATE290400T1 (de) Zusammensetzung zur behandlung von degenerativen gelenkerkrankungen
JO2231B1 (en) Derivatives of Trahydroperan and its use as a therapeutic agent
TNSN03065A1 (fr) Biopesticide compositions
WO2002053099A3 (fr) Methodes et compositions de traitement d'une parodontopathie
ATE535242T1 (de) Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
WO2007023281A3 (fr) Composes biologiquement actifs
WO2003072022A3 (fr) Formulations et traitements de trimethobenzamide par voie orale
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application